Lung Cancer Features Archive

General Oncology Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.

General Oncology Cancer Recurrence: Tackling a Valid Survivor Fear

Cancer Recurrence: Tackling a Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Lung Cancer Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Better collaboration between community and academic cancer centers could benefit patients.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Lung Cancer Checkpoint Inhibitor Pneumonitis in NSCLC

Checkpoint Inhibitor Pneumonitis in NSCLC

Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.

General Oncology Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Lung Cancer A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.

Lung Cancer Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC

Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC

The VEGFR/EGFR inhibitor anlotinib prolonged PFS and OS in Chinese patients with NSCLC, but additional studies are needed to determine its benefit in other populations.

Lung Cancer "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Lung Cancer Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer

Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer

Artificial intelligence techniques are being employed to build complex new multivariate prognostic models for patients with lung cancer and other malignancies.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Lung Cancer Re-treatment With Checkpoint Inhibitors in Some Patients With NSCLC May Be Feasible

Re-treatment With Checkpoint Inhibitors in Some Patients With NSCLC May Be Feasible

Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Lung Cancer The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations

The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations

The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.

Lung Cancer Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma

Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma

Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Lung Cancer Upfront Next-Generation Sequencing Is Faster, More Cost-Effective in Metastatic NSCLC

Upfront Next-Generation Sequencing Is Faster, More Cost-Effective in Metastatic NSCLC

The researchers argue that upfront next-generation sequencing should be the new standard of care.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Lung Cancer Role of BRAF Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

Role of BRAF Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Lung Cancer Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

The phase 3 study found the combination effective, regardless of tumor proportion score.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Lung Cancer Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Lung Cancer Lung Cancer: Predicting Response Checkpoint Inhibition

Lung Cancer: Predicting Response Checkpoint Inhibition

Assessing tumor mutational burden may help to determine which patients will respond.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Lung Cancer Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches

Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches

Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.

General Oncology Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Lung Cancer Exercise: A Growing Role in Lung Cancer Prevention, Treatment, and Survival

Exercise: A Growing Role in Lung Cancer Prevention, Treatment, and Survival

Regular exercise can help patients with cancer deal with issues related to weight gain during treatment.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Lung Cancer Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns

Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns

Study findings suggest that some clinicians are using immunotherapies in the types of patients not included in clinical trials.

Side Effect Management In the Clinic: Managing Malignant Pleural Effusions

In the Clinic: Managing Malignant Pleural Effusions

Management of malignant pleural effusions should be tailored to the particular patient, depending on preference, prognosis, and variety of underlying disease.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Lung Cancer Priming Lung Cancer to Respond to Immunotherapy: Findings and Current Research

Priming Lung Cancer to Respond to Immunotherapy: Findings and Current Research

One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

Lung Cancer Comprehensive Smoke-free Ordinances Reduce Risk of Lung Cancer

Comprehensive Smoke-free Ordinances Reduce Risk of Lung Cancer

People living in counties with strong smoke-free policies were 7.9% less likely to be diagnosed with lung cancer compared with those living in counties with no protection.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Lung Cancer Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance

Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance

The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.

Lung Cancer New Data Suggest Potential Role for c-MET Inhibition in EGFR TKI-Resistant NSCLC

New Data Suggest Potential Role for c-MET Inhibition in EGFR TKI-Resistant NSCLC

c-MET, although rarer than T790M, may be a promising therapeutic target for patients who progress on EGFR TKI therapy.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

Lung Cancer Durvalumab: Previous Findings and Current Research

Durvalumab: Previous Findings and Current Research

Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Lung Cancer NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Lung Cancer ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.

Lung Cancer Tumor Re-Biopsy May Be Best Option to Identify Cause of EGFR-TKI Resistance in NSCLC

Tumor Re-Biopsy May Be Best Option to Identify Cause of EGFR-TKI Resistance in NSCLC

Not conducting a second tissue biopsy could have dangerous implications for the patient according to a recent article.

Lung Cancer An Uncertain Future for Durvalumab in Lung Cancer Management

An Uncertain Future for Durvalumab in Lung Cancer Management

Durvalumab's optimal clinical role in managing lung cancer remains unclear and more robust predictive biomarkers are needed.

Renal Cell Carcinoma Sirolimus Use in Graft Versus Host Disease

Sirolimus Use in Graft Versus Host Disease

As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Lung Cancer Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC

Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC

SABR may be used to improve PFS, or potentially OS, among patients who have a good response to chemotherapy, targeted therapy, or immunotherapy.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Lung Cancer Overcoming Resistance to ALK Inhibition in Lung Cancer

Overcoming Resistance to ALK Inhibition in Lung Cancer

The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Lung Cancer Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

Q&A With Dr Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.

General Oncology Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

Lung Cancer Lung Cancer Treatment Shows Promise With TG4010 and CIMAvax-EGF Vaccine Therapies

Lung Cancer Treatment Shows Promise With TG4010 and CIMAvax-EGF Vaccine Therapies

Two vaccine therapies, TG4010 and CIMAvax-EGF, show promise for treating lung cancer. Developed and approved for use in Cuba, CIMAvax-EGF is now undergoing clinical study in the United States.

General Oncology Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.

Lung Cancer Q&A With Matthew Rabinowitz, PhD: Detecting Relapse by Liquid Biopsy

Q&A With Matthew Rabinowitz, PhD: Detecting Relapse by Liquid Biopsy

Cancer Therapy Advisor asked Dr Rabinowitz, founder and CEO of Natera, about the bespoke PCR technology and ongoing studies.

General Oncology Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Lung Cancer In Focus: Atezolizumab for Non-small Cell Lung Cancer

In Focus: Atezolizumab for Non-small Cell Lung Cancer

Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Lung Cancer Are Medicare Rules a Culprit of Low Lung Cancer Screening Rates?

Are Medicare Rules a Culprit of Low Lung Cancer Screening Rates?

Requirements for Medicare coverage of CT lung cancer screening might be a factor for low screening rates among high-risk smokers.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Lung Cancer Lung Cancer Immunotherapy in Elderly Patients: Cause for Optimism?

Lung Cancer Immunotherapy in Elderly Patients: Cause for Optimism?

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patients.

General Oncology Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

General Oncology Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

General Oncology Industry Payments Influence Research, Prescribing, and Advocacy

Industry Payments Influence Research, Prescribing, and Advocacy

Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.

General Oncology Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs